Sasha Jovanovic
4 min read
-
Thermo Fisher Scientific reported past third quarter 2026 results with sales of US$12.137b and net income of US$1.721b, with earnings per share from continuing operations modestly higher than a year earlier on both a basic and diluted basis.
-
Beyond near term figures, Thermo Fisher Scientific is tied to fast growing areas like synthetic gene circuits, viral genome sequencing, and population genomic screening. This points to meaningful exposure to AI enabled precision medicine and advanced bioproduction workflows.
-
We will look at how Thermo Fisher Scientific’s investment narrative is shaped by stronger quarterly earnings that support its AI driven tools strategy.
Scan Thermo Fisher Scientific’s AI heavy tools story against other potential breakouts by reviewing our hand picked 54 AI infrastructure stocks now.
Thermo Fisher Scientific Investment Narrative Recap
To own Thermo Fisher Scientific, you need to believe its tools, services and AI enabled platforms in pharma, biotech and advanced genomics keep pulling through demand even while some academic and government budgets remain soft. The Q3 2026 report, with higher sales, net income and EPS than a year earlier, supports that operating thesis rather than reshaping it.
In the near term, the key swing factor is how quickly higher value bioproduction, diagnostics and informatics scale relative to the drag from muted funding customers and the microbiology divestiture. The latest earnings do not remove that risk, but they provide some evidence that the portfolio mix shift is already helping profitability.
The most relevant new datapoint for this quarter is Thermo Fisher Scientific being highlighted across fast growing areas such as synthetic gene circuits, bead linked transposase kits and viral genome sequencing, where AI is integrated into design and analysis workflows. These are the kinds of tools that can deepen relationships with pharma and biotech customers that already generate most of the group’s revenue.
If these newer genomic and AI heavy platforms see broad adoption, they could reinforce the current catalyst of stronger pharma and biotech activity while also diversifying away from slower academic and government demand. Execution risk sits in integrating these technologies into smooth, end to end workflows at scale and doing so without stretching the balance sheet, given the business already carries a high level of debt.
Thermo Fisher Scientific’s narrative projects US$56.1b revenue and US$10.7b earnings by 2029. This rests on analysts assuming 5.8% yearly revenue growth and an earnings increase of about US$3.6b from US$7.1b today.
